iGENETECH has been recognized as one of the BDMT Global Top 40 Global Innovations for 2026 — an annual listing that identifies companies redefining the boundaries of technology-driven transformation across industries worldwide.
This recognition reflects the growing global relevance of the MoiM Dx Platform: a 16-plex molecular diagnostics system capable of delivering results in under 60 minutes, designed from the ground up for decentralized and point-of-care settings where laboratory infrastructure is limited or absent.
Why this matters
The diagnostics industry has long operated on a centralized model — samples travel to laboratories, not the other way around. MoiM challenges that assumption. By integrating sample-to-answer automation into a compact, field-deployable platform, iGENETECH enables clinical-grade molecular testing at the point of care: in hospitals without fully equipped labs, in remote clinics, in field settings across veterinary and food safety applications.
BDMT Global's recognition places iGENETECH alongside innovations being evaluated for commercial traction in the U.S. market — including access to the Boston investor and IVD stakeholder ecosystem through BDMT's network later in 2026.
What comes next
iGENETECH will be present at ADLM 2026 in Anaheim, California (July 26–30), where the MoiM platform will be showcased to diagnostics, animal health, food safety and beauty/wellbeing stakeholders. ADLM represents our first major North America-facing commercial milestone, and this recognition from BDMT Global strengthens the foundation from which we enter that conversation.
For partnership inquiries or to schedule a meeting at ADLM 2026, visit our Support page.
iGENETECH has been recognized as one of the BDMT Global Top 40 Global Innovations for 2026 — an annual listing that identifies companies redefining the boundaries of technology-driven transformation across industries worldwide.
This recognition reflects the growing global relevance of the MoiM Dx Platform: a 16-plex molecular diagnostics system capable of delivering results in under 60 minutes, designed from the ground up for decentralized and point-of-care settings where laboratory infrastructure is limited or absent.
Why this matters
The diagnostics industry has long operated on a centralized model — samples travel to laboratories, not the other way around. MoiM challenges that assumption. By integrating sample-to-answer automation into a compact, field-deployable platform, iGENETECH enables clinical-grade molecular testing at the point of care: in hospitals without fully equipped labs, in remote clinics, in field settings across veterinary and food safety applications.
BDMT Global's recognition places iGENETECH alongside innovations being evaluated for commercial traction in the U.S. market — including access to the Boston investor and IVD stakeholder ecosystem through BDMT's network later in 2026.
What comes next
iGENETECH will be present at ADLM 2026 in Anaheim, California (July 26–30), where the MoiM platform will be showcased to diagnostics, animal health, food safety and beauty/wellbeing stakeholders. ADLM represents our first major North America-facing commercial milestone, and this recognition from BDMT Global strengthens the foundation from which we enter that conversation.
For partnership inquiries or to schedule a meeting at ADLM 2026, visit our Support page.